Intercept Pharmaceuticals, Inc. (ICPT) Stock Rating Reaffirmed by Cantor Fitzgerald

Elias Hubbard
September 13, 2017

On Tuesday, August 1st, David Shapiro sold 1,118 shares of Intercept Pharmaceuticals stock. Considering that the stock daily volume of 5.91 million shares, this represents a pretty noteworthy shoot in volume.

As of quarter end Ubs Group Ag had acquired 2,695 shares growing its stake by 11.1%. This rating score is based on a 1-5 scale where a 5 would reveal a Strong Sell, a 4 indicates a Sell, 3 would equal to a hold, 2 means a Buy, and a rating of 1 would display a Strong Buy. Analyst's mean target price for ADXS is $20.67 while analysts mean recommendation is 1.60.

In trading on Tuesday, shares of Intercept Pharmaceuticals Inc (Symbol: ICPT) entered into oversold territory, hitting an RSI reading of 28.2, after changing hands as low as $90.53 per share. Latest closing price was 13.06% above its 50-day moving average and -22.37% below its 200-day moving average. Intercept Pharmaceuticals has a one year low of $91.50 and a one year high of $177.93. Intercept Pharmaceuticals, Inc. (ICPT) is now moving with downbeat trend. Company fiscal year is ending in October and analysts' consensus recommendation is Outperform for ADXS and estimated EPS for next quarter is $ -0.53. The business had revenue of $30.89 million for the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 543.35% and a negative return on equity of 135.24%. Market Cap is also the figure use to determine company's size, as opposed to using sales or total asset figures. Next quarter's EPS is forecasted to be $-3.44 and the next full year EPS is projected to be $-11.57. Intercept Pharmaceuticals had 41 analyst reports since August 10, 2015 according to SRatingsIntel. (NASDAQ:ICPT) in a research report sent to investors on Monday morning. If you are viewing this article on another publication, it was stolen and republished in violation of United States and worldwide trademark and copyright laws. BidaskClub upgraded Intercept Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Friday, June 23rd.

Traders are more bullish on the company recently if you take a look at the downtick in short interest. About 1.93 million shares traded or 293.99% up from the average. Insiders own 9.20% of the company's stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The stock was sold at an average price of $121.33, for a total transaction of $47,804.02. The disclosure for this sale can be found here.

Hedge funds have recently made changes to their positions in the business. Volume has increased in Tuesday's trading session by 5.46 million shares, but on a weak note. The biopharmaceutical company reported ($3.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.62) by $0.16. Jefferies Group LLC started coverage on Intercept Pharmaceuticals in a report on Monday, July 10th. The current consensus recommendation provided by covering analysts is 2.70. IFP Advisors Inc boosted its stake in shares of Intercept Pharmaceuticals by 128.1% in the second quarter. State Street Corp increased its position in shares of Intercept Pharmaceuticals by 7.3% during the first quarter. Following the sale, the chief executive officer now owns 611,718 shares of the company's stock, valued at $80,012,714.40. WFG Advisors LP now owns 888 shares of the biopharmaceutical company's stock valued at $108,000 after purchasing an additional 125 shares during the period.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has declined 14.52% since September 12, 2016 and is downtrending. The Firm is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases.

Other reports by Click Lancashire

Discuss This Article